Berndt Modig

Chief Executive Officer, Pharvaris

Search every verified Berndt Modig interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a November 2019 interview, Berndt Modig, CEO of Pharvaris, discussed the company's focus on developing oral therapies for hereditary angioedema (HAE), a rare genetic condition characterized by recurrent swelling attacks that can be life-threatening if they affect the airways. Modig stated that Pharvaris was founded by the core team responsible for developing icatibant, an injectable HAE treatment, and that its lead candidate, PHA121, is an orally available small molecule in clinical development. He noted that current HAE treatments are limited by invasive administration methods and that an oral option represents an unmet medical need for patients. Modig described HAE as having a prevalence between 1 in 10,000 and 1 in 50,000 people, with swelling attacks occurring in areas such as the hands, feet, face, and gastrointestinal tract. He emphasized that untreated airway swelling can be fatal. Modig directed listeners to the Pharvaris website for further information about the company and its upcoming trials.